Proteros and Eisai Announces Successful Completion of Collaboration
News May 07, 2013
Proteros biostructures GmbH has announced the successful completion of an integrated lead discovery collaboration with Eisai Co., Ltd.
Based on Proteros’ structure guided discovery platform, various series of Lead Compounds were developed within a period of 10 months.
The developed compound series showed single digit nanomolar Kd values, as well as optimized binding kinetics and kinetic selectivity.
Hits were identified out of the Proteros fragment library and the optimization process was driven by high quality protein crystallography as well as kinetic and thermodynamic profiling and the seamless interactions between Eisai and Proteros medicinal and computational chemists.
Dr. Lars Neumann, Vice President Discovery Projects and Project Manager stated: “We are very satisfied with the course of the project and are pleased to deliver the lead compound series to our partner Eisai Co., Ltd. We look forward to contributing further to the success of the Eisai research pipeline using our unique technology platform.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018